Stockscreener 앱 받기
8.55
4.14%
0.34
시간 외 거래:
8.48
-0.07
-0.82%
전일 마감가:
$8.21
열려 있는:
$8.2
하루 거래량:
1.18M
Relative Volume:
0.93
시가총액:
$558.52M
수익:
$141.31M
순이익/손실:
$-297.87M
주가수익비율:
-1.5853
EPS:
-5.3933
순현금흐름:
$-168.20M
1주 성능:
+7.68%
1개월 성능:
+10.89%
6개월 성능:
+3.76%
1년 성능:
+0.00%
1일 변동 폭
$8.20
$8.95
1주일 범위
$7.63
$8.95
52주 변동 폭
$5.37
$17.58
깅코 바이오웍스 홀딩스 Stock (DNA) Company Profile
명칭
Ginkgo Bioworks Holdings Inc
전화
(877) 442-5362
주소
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
8.55 | 537.62M | 141.31M | -297.87M | -168.20M | -5.3933 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
깅코 바이오웍스 홀딩스 Stock (DNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-15 | 다운그레이드 | BTIG Research | Neutral → Sell |
| 2024-05-10 | 다운그레이드 | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-06-02 | 다운그레이드 | Goldman | Neutral → Sell |
| 2023-05-11 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | 개시 | Berenberg | Buy |
| 2022-10-04 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-02 | 재개 | Cowen | Outperform |
| 2022-02-23 | 개시 | Goldman | Neutral |
| 2022-02-01 | 개시 | BofA Securities | Neutral |
| 2022-01-28 | 개시 | BofA Securities | Buy |
| 2022-01-07 | 개시 | BTIG Research | Buy |
| 2021-11-29 | 개시 | Jefferies | Buy |
| 2021-10-13 | 개시 | Raymond James | Outperform |
| 2021-10-12 | 개시 | William Blair | Outperform |
| 2021-09-20 | 개시 | HSBC Securities | Buy |
모두보기
깅코 바이오웍스 홀딩스 주식(DNA)의 최신 뉴스
Ginkgo Bioworks (DNA) director Henry Christian O receives 25,000 RSU equity grant - Stock Titan
Director Ross Fubini receives 25,000 RSUs at Ginkgo Bioworks (NYSE: DNA) - Stock Titan
Director at Ginkgo Bioworks (NYSE: DNA) granted 25,000 RSUs - Stock Titan
Ginkgo Bioworks (DNA) director Harry Sloan awarded 25,000 RSUs - Stock Titan
Ginkgo Bioworks Holdings, Inc. Files Form 8-K With SEC for June 2026 – Key Submission Details and Company Information 17 – Minichart - Minichart
Ginkgo Bioworks (NYSE: DNA) shareholders approve directors, Deloitte and executive pay - Stock Titan
Ginkgo Bioworks (DNA) Short Interest & Short Float | Updated Jun 2026 $DNA - MarketBeat
Austin Che (DNA) files Form 144 showing sales totaling tens of thousands of Class A shares - Stock Titan
Precision Trading with Ginkgo Bioworks Holdings Inc. Class A (DNA) Risk Zones - Stock Traders Daily
Ginkgo Bioworks Holdings, Inc. - MLQ.ai
Top Ginkgo Bioworks (DNA) Competitors 2026 - MarketBeat
Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm - TMX Newsfile
Technical Reactions to DNA Trends in Macro Strategies - Stock Traders Daily
Ginkgo Bioworks (NYSE: DNA) insider logs RSU vesting and small tax-related share sale - Stock Titan
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery - Investing News Network
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery - marketscreener.com
Ginkgo Bioworks, Tangible Scientific, And Inductive Bio Launch ADME-One High-Throughput ADME Platform - marketscreener.com
New AI lab service aims for fewer dead ends in drug discovery - Stock Titan
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts - MSN
Ginkgo Bioworks Holdings (DNA) Price Target Decreased by 11.11% to 10.88 - MSN
Steve Coen (DNA) files Form 144 to sell 307 Class A shares - Stock Titan
Ginkgo Bioworks Holdings Inc (DNA): What’s the Future of Autonomous Lab? - Yahoo Finance
DNA Technical Analysis | Trend, Signals & Chart Patterns | GINKGO BIOWORKS HOLDINGS INC (NYSE:DNA) - ChartMill
Trading the Move, Not the Narrative: (DNA) Edition - Stock Traders Daily
Ginkgo Bioworks Announces Presentations at the Upcoming American - GuruFocus
Viking Global (DNA) reports 3,577,128 shares, removes retired reporting person - Stock Titan
Ginkgo Bioworks Holdings, Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:DNA) 2026-05-13 - Seeking Alpha
Ginkgo Bioworks slumps 14% after projecting FY26 cash burn of $125M-$150M - MSN
Ginkgo outlines $125M-$150M 2026 cash burn guidance while expanding Nebula to 103 racks - MSN
Ginkgo Bioworks: Another Lost Year (NYSE:DNA) - Seeking Alpha
Austin Che files Form 144 to sell Class A shares (NASDAQ: DNA) - Stock Titan
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat - 富途牛牛
The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts - Yahoo Finance
The $59B Quiet Shift Reshaping How Patients Access Care - Benzinga
How The Ginkgo Bioworks (DNA) Story Is Shifting After The Biosecurity Divestiture And Target Cut - Yahoo Finance
William Blair Maintains Ginkgo Bioworks(DNA.US) With Sell Rating - Moomoo
TradingKey - TradingKey
Number of shareholders of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Ginkgo Bioworks Q1 Earnings Call Highlights - Barchart.com
Ginkgo Bioworks Earnings Call: Cash Rich, Revenue Pinched - TipRanks
DNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2026 Earnings Call Transcript - Insider Monkey
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price, News, Quote & History - Yahoo Finance
Ginkgo Bioworks slumps 14% after projecting FY26 cash burn of $125M-$150M (DNA:NYSE) - Seeking Alpha
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenging Waters with a Pioneering Vision - DirectorsTalk Interviews
Ginkgo Bioworks Previously Reported Fincl Results for Comparable Periods Retrospectively Recast >DNA - Moomoo
Earnings call transcript: Ginkgo Bioworks Q1 2026 sees revenue drop, restructuring efforts noted - Investing.com Canada
Ginkgo Bioworks : Q1 2026 Results (Dial-In Information) - marketscreener.com
깅코 바이오웍스 홀딩스 (DNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):